Inflammatory Bowel Disease Market expected to rise | Companies- Eli Lilly and Company, Gilead

Inflammatory Bowel Disease Market expected to rise | Companies- Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, expected to drive market The Inflammatory Bowel Disease market growth is driven by factors like increase in the prevalence of Inflammatory Bowel Disease, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Inflammatory Bowel Disease market report also offers comprehensive insights into the Inflammatory Bowel Disease market size, share, Inflammatory Bowel Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Inflammatory Bowel Disease market size growth forward.

Some of the key highlights from the Inflammatory Bowel Disease Market Insights Report: ●

●

●

Several key pharmaceutical companies, including Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, and others, are developing novel products to improve the Inflammatory Bowel Disease treatment outlook.

The total Inflammatory Bowel Disease market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.

As per DelveInsight analysis, the Inflammatory Bowel Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Inflammatory Bowel Disease Market Landscape Inflammatory Bowel Disease Overview Inflammatory bowel disease (IBD) is a term that describes disorders involving long-standing (chronic) inflammation of tissues in your digestive tract. Types of IBD include: Ulcerative colitis.

This condition involves inflammation and sores (ulcers) along the lining of your large intestine (colon) and rectum.

Inflammatory bowel disease (IBD) is a term that describes disorders involving long-standing (chronic) inflammation of tissues in your digestive tract. Types of IBD include: Ulcerative colitis. This condition involves inflammation and sores (ulcers) along the lining of your large intestine (colon) and rectum.

Crohn's disease. This type of IBD is characterized by inflammation of the lining of your digestive tract, which often can involve the deeper layers of the digestive tract. Crohn's disease most

commonly affects the small intestine. However, it can also affect the large intestine and uncommonly, the upper gastrointestinal tract.

Both ulcerative colitis and Crohn's disease usually are characterized by diarrhea, rectal bleeding, abdominal pain, fatigue and weight loss.

For some people, IBD is only a mild illness. For others, it's a debilitating condition that can lead to life-threatening complications.

Inflammatory Bowel Disease Symptoms Inflammatory bowel disease symptoms vary, depending on the severity of inflammation and where it occurs. Symptoms may range from mild to severe. You are likely to have periods of active illness followed by periods of remission.

Signs and symptoms that are common to both Crohn's disease and ulcerative colitis include: ● ● ● ● ● ●

Diarrhea Fatigue Abdominal pain and cramping Blood in your stool Reduced appetite Unintended weight loss

Do you know the treatment paradigms for different countries? Download our Inflammatory Bowel Disease Market Sample Report Recent breakthrough in the Inflammatory Bowel Disease ● ●

●

FDA approves first oral treatment for moderately to severely active Crohn’s disease: FDA has approved Rinvoq (upadacitinib) for adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Rinvoq is the first approved oral product available to treat moderately to severely active Crohn’s disease.

Patients should start with 45 mg of Rinvoq once daily for 12 weeks. Following the 12-week period, the recommended maintenance dosage is 15 mg once a day. A maintenance dosage of 30 mg once daily can be considered for patients with refractory, severe, or extensive Crohn’s disease.

Inflammatory Bowel Disease Epidemiology Segmentation DelveInsight’s Inflammatory Bowel Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Inflammatory Bowel Disease historical patient pools and forecasted Inflammatory Bowel Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further.

The Inflammatory Bowel Disease Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into: ●

Inflammatory Bowel Disease Prevalence

● ● ●

Age-Specific Inflammatory Bowel Disease Prevalence Gender-Specific Inflammatory Bowel Disease Prevalence Diagnosed and Treatable Cases of Inflammatory Bowel Disease

Visit for more @ Inflammatory Bowel Disease Epidemiological Insights Inflammatory Bowel Disease Treatment Market The Inflammatory Bowel Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Inflammatory Bowel Disease market trends by analyzing the impact of current Inflammatory Bowel Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

The most common medications used to treat IBD are antibiotics such as metronidazole and ciprofloxacin; ASA anti-inflammatory drugs such as Asacol, Azulfidine, Colazol, Pentasa, Rowasa and Lialda; steroids, such as prednisone, prednisolone or budesonide, immunomodulators such as Imuran(azathioprine), Purinethol, and methotrexate; biologics, such as REMICADE, HUMIRA, CIMZIA, ENTYVIO, STELARA and XELJANZ, nutritional therapy can be used to induce and maintain remission in Crohn’s disease.

There are various drugs currently being studied for the treatment of IBD. The Key players are Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, and others.

According to DelveInsight, the Inflammatory Bowel Disease market in 7MM is expected to witness a major change in the study period 2019-2032.

Inflammatory Bowel Disease Key Companies ● ● ● ● ●

Eli Lilly and Company Gilead Galapagos Protagonist Therapeutics Athos Therapeutics

For more information, visit Inflammatory Bowel Disease Market Analysis, Patient Pool, and Emerging Therapies Scope of the Inflammatory Bowel Disease Market Report:

● ●

10 Years Forecast 7MM Coverage

● ● ● ● ●

Descriptive overview of Inflammatory Bowel Disease, causes, signs and symptoms, diagnosis, treatment Comprehensive insight into Inflammatory Bowel Disease epidemiology in the 7MM Inflammatory Bowel Disease marketed and emerging therapies Inflammatory Bowel Disease companies Inflammatory Bowel Disease market drivers and barriers

Key Questions Answered in the Inflammatory Bowel Disease Market Report 2032:

● ● ● ●

What was the Inflammatory Bowel Disease market share distribution in 2019, and how would it appear in 2032?

What is the total Inflammatory Bowel Disease market size and the market size by therapy across the 7MM for the study period (2019-32)?

What are the important findings from 7MM, and which country will have the greatest Inflammatory Bowel Disease market size from 2019-32?

During the study period (2019-2032), at what CAGR is the Inflammatory Bowel Disease market projected to expand at 7MM?

Table of Contents: 1 Inflammatory Bowel Disease Market Key Comprehensive Insights 2 Inflammatory Bowel Disease Market Report Introduction 3 Competitive Intelligence Analysis for Inflammatory Bowel Disease 4 Inflammatory Bowel Disease Market Analysis Overview at a Glance 5 Executive Summary of Inflammatory Bowel Disease 6 Inflammatory Bowel Disease Epidemiology and Market Methodology 7 Inflammatory Bowel Disease Epidemiology and Patient Population 8 Inflammatory Bowel Disease Patient Journey 9 Inflammatory Bowel Disease Treatment Algorithm, Inflammatory Bowel Disease Current Treatment, and Medical Practices 10 Key Endpoints in Inflammatory Bowel Disease Clinical Trials 11 Inflammatory Bowel Disease Marketed Therapies 12 Inflammatory Bowel Disease Emerging Therapies 13 Inflammatory Bowel Disease: 7 Major Market Analysis 14 Attribute analysis 15 Access and Reimbursement Overview of Inflammatory Bowel Disease 16 Inflammatory Bowel Disease Market Key Opinion Leaders Reviews 18 Inflammatory Bowel Disease Market Drivers 19 Inflammatory Bowel Disease Market Barriers 20 SWOT Analysis 21 Disclaimer 22 DelveInsight Capabilities 23 About DelveInsight

Related Reports: Inflammatory Bowel Disease Epidemiology 2032 DelveInsight's "Inflammatory Bowel Disease - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Inflammatory Bowel Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight: DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Contact Us: Kritika Rehani krehani@delveinsight.com +91-9650213330 www.delveinsight.com